Yan Wang et al. [22] evaluated the prognostic significance of AFP status in HCC patients after transarterial chemoembolization (TACE) and receiving the chemotherapeutic agents of TACE, including fluorouracil and cisplatin, and reported that patients with AFP-negative status have a better treatment response and prognosis after TACE than AFP-positive HCC patients. The gene discussed is AFP; the disease is hepatocellular carcinoma.